Update on Joint Venture and Placing

RNS Number : 9051R
Benchmark Holdings PLC
19 June 2018
 

Benchmark Holdings plc 

("Benchmark" or the "Company")

Update on Joint Venture and Placing

Benchmark (LSE:BMK), the aquaculture health, advanced nutrition, and genetics business, is today providing an update on its agreement to fund a Chilean breeding and genetics joint venture with Empresas AquaChile S.A. (the "JV") and the related placing to raise £19.0 million (before expenses) (the "Placing").

Further to the announcement of the Joint Venture and Placing made on 8 June 2018, Benchmark is pleased to announce that it has successfully received Bank Approval and the Placing Shares (34,545,455 ordinary shares of 0.1p each in the Company) are therefore expected to be admitted to trading on AIM at or around 8.00 a.m. (London time) on 25 June 2018.

The Company's total issued share capital following completion of the Placing will consist of 557,075,584 ordinary shares of 0.1 pence each with one voting right per share (assuming no options or warrants are exercised in the period between this announcement and Admission). The above figure of 557,075,584 may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company following Admission.

Capitalised terms used but not defined in this announcement have the same meanings as set out in the announcement of the Company released at 7.00am (London time), 8 June 2018.

For further information, please contact:


Benchmark Holdings plc

Tel:  020 7920 3150

Malcolm Pye, CEO


Ivonne Cantu, Investor Relations Director


Rachel Aninakwah, Communications






Numis

Tel:  020 7260 1000

Michael Meade, Freddie Barnfield, Freddie Naylor-Leyland  (NOMAD)


James Black  (Corporate Broking)




MHP Communications

Tel:  020 3128 8742

Katie Hunt / Reg Hoare / Alistair de Kare-Silver


 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCSFDFIUFASESM
UK 100

Latest directors dealings